EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Thyroid differentiation profile for differentiated thyroid cancer

Anthony J McGoron iD, Jose M Garcia, Burulça Uluvar, Seza A Gulec

Endocrine Oncology · 01.01.2025 · 5 (1)

DOI: 10.1530/eo-24-0072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 24.01.2025. Verfasst von Anthony J McGoron und 3 weiteren Autor:innen. Beteiligte Einrichtung: Florida International University, College of Engineering and Computing, Miami, Florida, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioactive iodine (RAI) treatment is an established therapeutic tool for ‘differentiated thyroid cancers’. The therapeutic effectiveness is linked to the preservation of the iodine-concentrating ability of the neoplastic tissue, a unique, inherent quality of a normal thyroid gland. Iodine concentration is a function involving the expression of transport proteins and organification. Thyroid differentiation score (TDS) is an integrated quantity, first introduced by The Cancer Genome Atlas (TCGA), conveying the relative expression of proteins involved in histogenesis, morphologic and functional differentiation of thyroid tissue. The concept is well described for the expression of metabolic suppression of thyroid cancers associated with RAI-refractoriness. We evaluated the mRNA expressions of thyroid metabolomics-specific genes, comparing normal thyroid to neoplastic tissue in a cohort where patient-specific paired data were available. Fifty-nine papillary thyroid cancer samples from the TCGA project with matched tumor-normal tissue samples were analyzed. Of the 59 samples, 29 contained a BRAFV600E mutation, seven a RAS mutation, 10 a mutation other than BRAF or RAS, and 14 either no mutation or an unknown mutation. Our analysis demonstrated that there was a significant downregulation of the RAI theranostic transcriptome, much more significant in BRAF-initiated cancers vs RAS-initiated ones. There was also notable heterogeneity in respective mutational categories where individual assessment of the thyroid differentiation profile (TDP) would potentially be clinically relevant for RAI treatment planning. Determination of TDP and development of a theranostic TDS may have an impact on clinical decision making as to the extent of thyroidectomy and postoperative RAI therapy.

Schlagwörter

Stichwörter der Autor:innen

BRAFERKMAPK pathwayRAI refractoryRASTKIdifferentiated thyroid cancerpapillary thyroid cancerradioactive iodineredifferentiationthyroid cancerthyroid differentiation scorethyrosine kinase

Autor:innen und Institutionen

  • Florida International University, College of Engineering and Computing, Miami, Florida, USA.
  • Florida International University, College of Arts Science and Education, Miami, Florida, USA.
  • Computational Medicine, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • HCA Florida Aventura Hospital, Aventura, Florida, USA.
  • Miami Cancer Research Center, Miami, Florida, USA.

ORCID-Profile: Anthony J McGoron

Zitieren

APA

McGoron, A. J., Garcia, J. M., Uluvar, B., & Gulec, S. A. (2025). Thyroid differentiation profile for differentiated thyroid cancer. Endocrine Oncology, 5(1). https://doi.org/10.1530/eo-24-0072

Vancouver

McGoron AJ, Garcia JM, Uluvar B, Gulec SA. Thyroid differentiation profile for differentiated thyroid cancer. Endocrine Oncology. 2025;5(1). doi:10.1530/eo-24-0072

BibTeX
@article{McGoron2025,
  author = {McGoron, Anthony J and Garcia, Jose M and Uluvar, Burulça and Gulec, Seza A},
  title = {Thyroid differentiation profile for differentiated thyroid cancer},
  journal = {Endocrine Oncology},
  year = {2025},
  volume = {5},
  number = {1},
  doi = {10.1530/eo-24-0072}
}
Kostenlos starten →